LV-ChAT-GFP-WPRE Lentivirus Ready to Package
Lentivirus - 2. page
Overview of Lentivirus Pseudotypes
Overview of Lentivirus Pseudotypes Family Genus Species Vector References Rhabdoviridae Vesiculovirus Vesicular stomatitis virus (Indiana virus) HIV-1 [Akkina, 1996][Naldini, 1996][Reiser, 1996] HIV-2 [Poeschla, 1998a] FIV [Poeschla, 1998b] EIAV [Olsen, 1998] […]
LV-HB9-Citrine-WPRE Lentivirus Ready to Package
LV-HB9-Citrine-WPRE Lentivirus Ready to Package
A universal DNA qPCR based approach for lentivirus titration
A quantitative, DNA-based, real-time PCR approach to determine the number of lentivirus particles that are present in vector preparations was reported. In this approach, the minus strong-stop cDNA fragment that is present in viral capsids serves as […]
Primers targeting minus strong-stop cDNA fragment for lentivirus titration
Forward: 5′-AGCTTGCCTTGAGTGCTTCA-3′ Reverse: 5′-TGACTAAAAGGGTCTGAGGGA-3′
Optimal MOIs for Some Cells Infected with Lentivirus
Cell line Tissue Cancer/cell type Species MOI A431 Epithelial Carcinoma Human 5 A549 Lung Carcinoma Human 5 Astrocytes Nervous system Primary Human 1 B16-F10 Epithelial Melanoma, metastatic Mouse 5 BMM Bone Marrow Primary Human 8 […]
Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.
On July 1, 2014, the United States Food and Drug Administration granted ‘breakthrough therapy’ designation to CTL019, the anti-CD19 chimeric antigen receptor T-cell therapy developed at the University of Pennsylvania. […]
The CAR T-Cell Race
Tumor-targeting T-cell therapies are generating remarkable remissions in hard-to-beat cancers—and attracting millions of dollars of investment along the way. By Vicki Brower | April 1, 2015 BUILDING A BETTER T-CELL: […]
CAR T-CELL BIOTECH IPOs
Company Date Value Kite Pharma June 2014 $134.1 million Bellicum December 2014 $160 million Juno December 2014 $264.6 million Cellectis March 2015 $228 million
CAR T-CELL DEALS
Institution/Company Date Partner Terms University of Pennsylvania August 2012 Novartis Undisclosed Celgene March 2013 Bluebird Bio, Baylor College of Medicine Unspecified upfront payment plus up to $225 million per product […]